Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
October 10, 2024 07:00 ET
|
Avacta Group
10 October 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024...
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
October 10, 2024 02:00 ET
|
Avacta Group
10 OctoberAvacta Group plc(“Avacta” or “the Group” or “the Company”)Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium...
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
September 14, 2024 03:00 ET
|
Avacta Group
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...
Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
September 08, 2024 18:05 ET
|
Avacta Group
8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress ...
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
July 08, 2024 08:15 ET
|
Avacta Group
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life...
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
April 05, 2024 16:30 ET
|
Avacta Group
5 April 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company...
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
March 05, 2024 16:30 ET
|
Avacta Group
5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a...
Appointment of Chief Business Officer
December 19, 2023 07:00 ET
|
Avacta Group
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical...
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
December 13, 2023 07:00 ET
|
Avacta Group
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...
Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 05, 2023 02:00 ET
|
Avacta Group
5 October 2023 Avacta Group plc (“Avacta” or the “Group” or the “Company”) Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International...